Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 4
2012 2
2014 2
2015 1
2016 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents.
Persaud D, Patel K, Karalius B, Rainwater-Lovett K, Ziemniak C, Ellis A, Chen YH, Richman D, Siberry GK, Van Dyke RB, Burchett S, Seage GR 3rd, Luzuriaga K; Pediatric HIV/AIDS Cohort Study. Persaud D, et al. JAMA Pediatr. 2014 Dec;168(12):1138-46. doi: 10.1001/jamapediatrics.2014.1560. JAMA Pediatr. 2014. PMID: 25286283 Free PMC article.
Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.
Kuhn L, Coovadia A, Strehlau R, Martens L, Hu CC, Meyers T, Sherman G, Hunt G, Persaud D, Morris L, Tsai WY, Abrams EJ. Kuhn L, et al. Lancet Infect Dis. 2012 Jul;12(7):521-30. doi: 10.1016/S1473-3099(12)70051-8. Epub 2012 Mar 16. Lancet Infect Dis. 2012. PMID: 22424722 Free PMC article. Clinical Trial.
Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.
Moorthy A, Gupta A, Bhosale R, Tripathy S, Sastry J, Kulkarni S, Thakar M, Bharadwaj R, Kagal A, Bhore AV, Patil S, Kulkarni V, Venkataramani V, Balasubramaniam U, Suryavanshi N, Ziemniak C, Gupte N, Bollinger R, Persaud D. Moorthy A, et al. PLoS One. 2009;4(1):e4096. doi: 10.1371/journal.pone.0004096. Epub 2009 Jan 1. PLoS One. 2009. PMID: 19119321 Free PMC article. Clinical Trial.
Analysis of the optimal cut-point for HIV-p24 antigen testing to diagnose HIV infection in HIV-exposed children from resource-constrained settings.
Tamhane M, Gautney B, Shiu C, Segaren N, Jeannis L, Eustache C, Simeon-Fadois Y, Chen YH, De D, Irivinti S, Tamma P, Thompson CB, Khamadi S, Siberry GK, Persaud D. Tamhane M, et al. J Clin Virol. 2011 Apr;50(4):338-41. doi: 10.1016/j.jcv.2011.01.012. Epub 2011 Feb 16. J Clin Virol. 2011. PMID: 21330193 Free PMC article.
Soluble CD14: An Independent Biomarker for the Risk of Mother-to-Child Transmission of HIV in a Setting of Preexposure and Postexposure Antiretroviral Prophylaxis.
Shivakoti R, Gupta A, Ray JC, Uprety P, Gupte N, Bhosale R, Mave V, Patil S, Balasubramanian U, Kinikar A, Bharadwaj R, Bollinger RC, Persaud D. Shivakoti R, et al. J Infect Dis. 2016 Mar 1;213(5):762-5. doi: 10.1093/infdis/jiv479. Epub 2015 Oct 6. J Infect Dis. 2016. PMID: 26443598 Free PMC article.
Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission.
Persaud D, Bedri A, Ziemniak C, Moorthy A, Gudetta B, Abashawl A, Mengistu Y, Omer SB, Isehak A, Kumbi S, Adamu R, Lulseged S, Ashworth R, Hassen E, Ruff A; Ethiopian Swen Study Team. Persaud D, et al. AIDS Res Hum Retroviruses. 2011 Aug;27(8):823-9. doi: 10.1089/aid.2010.0346. Epub 2011 Feb 25. AIDS Res Hum Retroviruses. 2011. PMID: 21241214 Free PMC article. Clinical Trial.